SEMA4A

SEMA4A
Identifiers
AliasesSEMA4A, CORD10, RP35, SEMAB, SEMB, semaphorin 4A
External IDsOMIM: 607292; MGI: 107560; HomoloGene: 8425; GeneCards: SEMA4A; OMA:SEMA4A - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001163489
NM_001163490
NM_001163491
NM_013658

RefSeq (protein)

NP_001156961
NP_001156962
NP_001156963
NP_038686

Location (UCSC)Chr 1: 156.15 – 156.18 MbChr 3: 88.34 – 88.37 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Semaphorin-4A is a protein that in humans is encoded by the SEMA4A gene.[5][6]

Function

SEMA4A is a member of the semaphorin family of soluble and transmembrane proteins. Semaphorins are involved in guidance of axonal migration during neuronal development and in immune responses.[supplied by OMIM][6]

Clinical significance

A germline variant in SEMA4A (V78M) has been demonstrated to confer risk for colorectal cancer type X.[7]

Recently it has been identified as a novel therapeutic target in Multiple myeloma.[8]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000196189Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028064Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Püschel AW, Adams RH, Betz H (May 1995). "Murine semaphorin D/collapsin is a member of a diverse gene family and creates domains inhibitory for axonal extension". Neuron. 14 (5): 941–948. doi:10.1016/0896-6273(95)90332-1. PMID 7748561.
  6. ^ a b "Entrez Gene: SEMA4A sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A".
  7. ^ Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, et al. (October 2014). "Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X". Nature Communications. 5: 5191. Bibcode:2014NatCo...5.5191S. doi:10.1038/ncomms6191. PMC 4214414. PMID 25307848.
  8. ^ Anderson GS, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, et al. (April 2022). "Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma". Blood. 139 (16): 2471–2482. doi:10.1182/blood.2021015161. PMC 11022854. PMID 35134130.

Further reading